General
Preferred name
PROCARBAZINE
Synonyms
PROCARBAZINE HYDROCHLORIDE ()
NSC-77213 HCl ()
Procarbazine HCl ()
Procarbazine HCl ()
Procarbazine (hydrochloride) ()
Procarbazine hydrochlorideProcarbazineMatulanePCB hydrochlorideIbenzmethyzine hydrochloridep-(N'-methylhydrazinomethyl)-N-isopropylbenzamide hydrochlorideMBHNatulanNathulaneNatunalar ()
RO-4-6467 ()
Procarbacine ()
Procarbazina ()
RO-4-6467 FREE BASE ()
Natulan ()
Ibenzmethyzine hydrochloride ()
NCI-C 01810 ()
NSC-77213 ()
Procarbazini hydrochloridum ()
RO-4-6467/1 ()
NCI-C-01810 ()
RO 4-646711 ()
RO 4 6467/1 ()
RO-4-6467 HYDROCHLORIDE ()
RO 4-6467/1 ()
Matulane ()
P&D ID
PD001685
CAS
671-16-9
366-70-1
Tags
available
prodrug
drug
Approved by
FDA
First approval
1969
Drug indication
Glioblastoma multiforme
Hodgkins lymphoma
Hodgkin lymphoma
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Procarbazine is a DNA alkylating agent.
(GtoPdb)
DESCRIPTION
Procarbazine Hydrochloride is an orally active alkylating agent, with anticancer activity. Procarbazine Hydrochloride can be used in Hodgkin's disease research[1][2].
PRICE
29
DESCRIPTION
inducer of DNA damage
(Informer Set)
DESCRIPTION
Procarbazine Hydrochloride is an alkylating agent, with anticancer activity.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Procarbazine hydrochloride (NSC-77213 HCl) is the hydrochloride salt of a methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
27
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
Informer Set
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
65
Molecular Weight
221.15
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
1
Aromatic Ring Count
1
cLogP
1.05
TPSA
53.16
Fraction CSP3
0.42
Chiral centers
0.0
Largest ring
6.0
QED
0.65
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Compound status
FDA
MOA
DNA alkylator
DNA/RNA Synthesis inhibitor
monoamine oxidase inhibitor
Target
DNA
DNA alkylator/crosslinker
DNA/RNA Synthesis
Indication
Hodgkin's lymphoma
Therapeutic Class
Anticancer Agents
Pathway
Cell Cycle/Checkpoint
DNA Damage/DNA Repair
Cell Cycle/DNA Damage
Source data
